Hepatocyte-specific expression of human carboxylesterase 2 attenuates nonalcoholic steatohepatitis in mice
Yanyong Xu, Xiaoli Pan, Shuwei Hu, Yingdong Zhu, Fathima N. Cassim Bawa, Yuanyuan Li, Liya Yin, Yanqiao Zhang
2020American Journal of Physiology-Gastrointestinal and Liver Physiology24 citationsDOIOpen Access PDF
Abstract
Human CES2 attenuates high-fat/cholesterol/fructose diet-induced steatohepatitis and reverses steatohepatitis in db/db mice. Mechanistically, human CES2 induces lipolysis, fatty acid and glucose oxidation, and inhibits hepatic glucose production, inflammation, lipid oxidation, and apoptosis. Our data suggest that human CES2 may be targeted for treatment of non-alcoholic steatohepatitis (NASH).
Topics & Concepts
SteatohepatitisEndocrinologyInternal medicineLipogenesisFatty liverLipolysisSteatosisNonalcoholic fatty liver diseaseBiologyHepatocyteLipid dropletChemistryLipid metabolismBiochemistryAdipose tissueMedicineDiseaseIn vitroLiver Disease Diagnosis and TreatmentLipid metabolism and biosynthesisDiet, Metabolism, and Disease